Adaptive Biotechnologies CPO trades 95,842 shares
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and pre-planned share sales.
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and pre-planned share sales. On July 1–2, 2026, Lo exercised stock options covering 75,621 shares of common stock and sold 95,842 shares in open-market transactions at weighted average prices in the low $20s per share.
The filing states these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were pre-scheduled. After the transactions, Lo directly held 230,713 shares of common stock, plus 2,500 shares held indirectly through a spouse.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
20 txns
Insider
LO FRANCIS
Role
Chief People Officer
Sold
95,842 shs ($2.16M)
Approx. gross sale proceeds
$2.16M
Approx. exercise cost
$662K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 12,626 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 12,600 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 12,637 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,626 | $7.80 | $98K |
| Exercise | Common Stock | 12,600 | $12.14 | $153K |
| Exercise | Common Stock | 12,637 | $8.46 | $107K |
| Sale | Common Stock | 44,838 | $22.59 | $1.01M |
| Exercise | Stock Option (right to buy) | 3,500 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 3,300 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 12,206 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 4,688 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 14,064 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,500 | $7.80 | $27K |
| Exercise | Common Stock | 3,300 | $12.14 | $40K |
| Exercise | Common Stock | 12,206 | $8.46 | $103K |
| Exercise | Common Stock | 4,688 | $3.99 | $19K |
| Exercise | Common Stock | 14,064 | $8.12 | $114K |
| Sale | Common Stock | 8,743 | $22.18 | $194K |
| Sale | Common Stock | 42,261 | $22.50 | $951K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 483,368 contracts (Direct);
Common Stock — 230,713 shares (Direct);
Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (8)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.48 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.49 to $22.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The option is fully vested and exercisable.
- F6. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F7. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
- F8. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Key Figures
Shares sold: 95,842 shares
Shares from option exercises: 75,621 shares
Post-transaction direct holdings: 230,713 shares
+4 more
7 metrics
Shares sold
95,842 shares
Total open-market sales of common stock reported
Shares from option exercises
75,621 shares
Total shares acquired via option exercises (M code)
Post-transaction direct holdings
230,713 shares
Common stock held directly after reported transactions
Indirect holdings via spouse
2,500 shares
Common stock held indirectly through spouse as of July 1, 2026
Sale price example
$22.59 per share
Weighted average price for 44,838-share sale on July 2, 2026
Option exercise price
$3.99 per share
Exercise price for one stock option series exercised July 1, 2026
Option exercise price
$12.14 per share
Exercise price for another stock option series exercised
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (right to buy), open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported for this transaction is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Adaptive Biotechnologies (ADPT) executive Francis Lo report in this Form 4?
Francis Lo reported exercising stock options for 75,621 shares and selling 95,842 shares of Adaptive Biotechnologies common stock. These transactions occurred on July 1–2, 2026 and involved open-market sales at weighted average prices in the low $20s per share.
Were Francis Lo’s ADPT stock sales made under a Rule 10b5-1 plan?
Yes. The filing states all reported transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025. Such plans pre-schedule trades, so the timing reflects a pre-arranged program rather than ad hoc market-timing decisions by the executive.
AI-generated analysis. How Rhea-AI works. Not financial advice.
